Hepatitis C News and Research

Latest Hepatitis C News and Research

HTDS' Hepatitis A vaccine receives GMP Certificate from the Russian FDA

HTDS www.htdsmedical.com (HTDS) - The issuer's China based operating subsidiary Mellow Hope www.mellowhope.com is pleased to announce that its Hepatitis A Live Attenuated Vaccine (Brand name: Mevac-A) associate operation plant has obtained the GMP Certificate (Good Manufacturing Practice See Description http://en.wikipedia.org/wiki/Good_manufacturing_practice) from the Russian FDA. http://www.who.int/hiv/HIVCP_RUS.pdf

8 Oct 2009

Needlestick injuries in home care nursing can also affect patients

Patients continue to enter home healthcare ''sicker and quicker," often with complex health problems that may require extensive nursing care. This increases the risk of needlestick injuries in home healthcare nurses.

8 Oct 2009

Amarillo Biosciences, Intas Pharmaceuticals enter strategic partnership to combat influenza in India

Amarillo Biosciences, Inc. today announced that it has agreed to a strategic partnership with Intas Pharmaceuticals Limited (Intas), one of the top 20 pharmaceutical companies in India, whereby Intas will sponsor clinical trials of ABI's orally administered interferon-alpha lozenges in order to combat influenza. Intas will pay ABI a royalty on net sales after marketing approval is obtained in India.

8 Oct 2009

Idera Pharmaceuticals commences phase 1 IMO-2125 clinical trial for chronic HCV infection

Idera Pharmaceuticals, Inc. today announced that patient treatment has been initiated in a phase 1 clinical trial evaluating IMO-2125 in combination with ribavirin in treatment-naive patients with chronic hepatitis C virus (HCV) infection. IMO-2125 is a novel agonist of Toll-like Receptor (TLR) 9.

7 Oct 2009

GlobeImmune to present an abstract of GI-5005 drug at AASLD's annual meeting

GlobeImmune Inc. today announced that a late breaking abstract related to GI-5005, its investigational hepatitis C virus (HCV) product candidate, has been accepted for presentation at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which will take place Oct. 31 through Nov. 4, 2009, in Boston, Mass.

7 Oct 2009

PSI-879 nominated as second development candidate for treating HCV infection

Pharmasset, Inc. announced today the nomination of PSI-352879 (PSI-879) as a second development candidate from two series of purine analogs for the treatment of chronic hepatitis C virus (HCV) infection.

7 Oct 2009

PDS Biotechnology's Versamune-based immunotherapy drug demonstrates safety in preclinical studies

PDS Biotechnology Corporation today announced that the company has completed GLP toxicology studies of its lead HPV-cancer product. The studies, which included pharmacokinetic (PK) and adsorption, bio-distribution and excretion (ADE) studies in addition to the evaluation of toxicity, all demonstrated a very safe profile of the drug and PDS Biotech's platform Versamune((TM)) technology.

6 Oct 2009

Hepatitis B Foundation calls for consistent monitoring and referral of HBV infected children

An expert panel of nationally recognized pediatric liver specialists convened by the Hepatitis B Foundation is calling for more consistent monitoring and referral of children chronically infected with the hepatitis B virus (HBV). The panel's recommendations for pediatricians and other primary care practitioners stress the need for routine monitoring of children with chronic HBV infections, and timely consultation with a pediatric liver specialist.

6 Oct 2009

FDA Advisory Committee approves Peginterferon alfa-2b for treating metastatic melanoma

Enzon Pharmaceuticals, Inc. today announced that the FDA Oncologic Drug Advisory Committee voted in favor of recommending approval of PEGINTRON® as a treatment in addition to surgery in patients with metastatic melanoma.

6 Oct 2009

New study to boost immune cells for pathogen resistance and vaccine efficacy in elderly

A new study from the Trudeau Institute in Saranac Lake, New York, demonstrates that immune system cells important for both pathogen resistance and vaccine efficacy live longer in older animals but because of this longevity acquire functional defects. The work may provide new targets for boosting immune system function in older individuals.

6 Oct 2009

Schering-Plough receives FDA recommendation approval for PEGINTRON

Schering-Plough Corp. announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval by a vote of six to four for PEGINTRON® (pegylated interferon alfa-2b) in the adjuvant treatment of patients with Stage III malignant melanoma.

6 Oct 2009

ArQule completes patient enrollment in ARQ 197 Phase 2 trial for non-small cell lung cancer

ArQule, Inc. (Nasdaq: ARQL) today announced that patient enrollment in a Phase 2 trial with ARQ 197 in non-small cell lung cancer (NSCLC) has been completed.

5 Oct 2009

Preclinical study results of AVL-181 protease inhibitor presented

Avila Therapeutics, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on its highly selective, pan-genotype, small molecule Hepatitis C Virus (HCV) protease inhibitor, AVL-181.

5 Oct 2009

NanoViricides completes a number of financing activities

NanoViricides, Inc. (the "Company"), announced today that it has completed a number of financing activities.

5 Oct 2009

Former President Clinton awards certification for new clean water system

The first chlorination system designed for cities in poor countries is now operating in Port-au-Prince, Haiti, announced Andrew Weiss at the Clinton Global Initiative (CGI) meeting in New York last week. "It's a great success," said Weiss.

5 Oct 2009

Bristol-Myers Squibb to present new data on BARACLUDE and other compounds at the AASLD 2009

New data on four Bristol-Myers Squibb Company (NYSE:BMY) compounds will be presented at the 60th annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston from October 30 to November 3.

3 Oct 2009

New technique for blood diagnosis developed

If a person loses a large amount of blood the consequences can be critical. That's why adequate quantities of donated blood have to be kept available in hospitals and blood banks.

3 Oct 2009

Phase 1b clinical trial results of PEG-Interferon lambda to be presented

Bristol-Myers Squibb Company and ZymoGenetics, Inc. (NASDAQ:ZGEN) announced that final results from a Phase 1b clinical trial in patients with hepatitis C (HCV) treated with PEG-Interferon lambda, a new class of interferon, in combination with ribavirin will be presented at the American Association for the Study of Liver Diseases (AASLD) annual meeting October 30–November 3, 2009, in Boston.

3 Oct 2009

New study underscores lack of appropriate government action to ensure safety of vaccines

A new study in the leading scientific journal NeuroToxicology lends further credence to parents and scientists concerned about an increasingly aggressive childhood vaccine schedule and toxic vaccine components.

2 Oct 2009

China's State Intellectual Property Bureau grants patent for Aoxing Ganbao

Biostar Pharmaceuticals, Inc. ("Biostar" or "the Company"), a Xianyang-based developer, manufacturer and supplier of pharmaceutical products and medical nutrients addressing a variety of diseases and conditions, today announced it has received a patent from China's State Intellectual Property Bureau for its Aoxing Ganbao product. The patent number is 551073.

2 Oct 2009

Hepatitis C News and Research

Latest Hepatitis C News and Research

HTDS' Hepatitis A vaccine receives GMP Certificate from the Russian FDA

Needlestick injuries in home care nursing can also affect patients

Amarillo Biosciences, Intas Pharmaceuticals enter strategic partnership to combat influenza in India

Idera Pharmaceuticals commences phase 1 IMO-2125 clinical trial for chronic HCV infection

GlobeImmune to present an abstract of GI-5005 drug at AASLD's annual meeting

PSI-879 nominated as second development candidate for treating HCV infection

PDS Biotechnology's Versamune-based immunotherapy drug demonstrates safety in preclinical studies

Hepatitis B Foundation calls for consistent monitoring and referral of HBV infected children

FDA Advisory Committee approves Peginterferon alfa-2b for treating metastatic melanoma

New study to boost immune cells for pathogen resistance and vaccine efficacy in elderly

Schering-Plough receives FDA recommendation approval for PEGINTRON

ArQule completes patient enrollment in ARQ 197 Phase 2 trial for non-small cell lung cancer

Preclinical study results of AVL-181 protease inhibitor presented

NanoViricides completes a number of financing activities

Former President Clinton awards certification for new clean water system

Bristol-Myers Squibb to present new data on BARACLUDE and other compounds at the AASLD 2009

New technique for blood diagnosis developed

Phase 1b clinical trial results of PEG-Interferon lambda to be presented

New study underscores lack of appropriate government action to ensure safety of vaccines

China's State Intellectual Property Bureau grants patent for Aoxing Ganbao

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Hepatitis C News and Research

Latest Hepatitis C News and Research

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in